Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran fires one of largest barrages in weeks ahead of Passover - 2Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- 3Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- 4SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- 5An Aide On Upgrading Your FICO rating
- Florida has quietly become America's execution capital
- Figure out how to Consolidate a Brain science Certificate with Social Work
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life
- What is the Significant Tech Expertise to Master Today?
- Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- Vote In favor of Your Favored Pet Consideration Administration
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
